Vita Life Sciences Limited (ASX:VLS)
2.760
0.00 (0.00%)
Sep 11, 2026, 11:25 AM AEST
Vita Life Sciences Revenue
Vita Life Sciences had revenue of 48.31M AUD in the half year ending June 30, 2026, with 22.44% growth. This brings the company's revenue in the last twelve months to 96.03M, up 12.19% year-over-year. In the year 2025, Vita Life Sciences had annual revenue of 93.27M with 17.31% growth.
Revenue (ttm)
96.03M
Revenue Growth
+12.19%
P/S Ratio
1.62
Revenue / Employee
274.37K
Employees
350
Market Cap
155.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 93.27M | 13.77M | 17.31% |
| Dec 31, 2024 | 79.51M | 6.08M | 8.28% |
| Dec 31, 2023 | 73.43M | 6.54M | 9.78% |
| Dec 31, 2022 | 66.89M | 9.78M | 17.14% |
| Dec 31, 2021 | 57.10M | 10.62M | 22.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vitura Health | 131.16M |
| Little Green Pharma | 75.50M |
| Medical Developments International | 42.57M |
| ECS Botanics Holdings | 21.02M |
| IDT Australia | 20.38M |
| Epsilon Healthcare | 13.58M |
| Peak Processing | 12.51M |
| Cann Group | 9.65M |
Vita Life Sciences News
- 24 days ago - Vita Life Sciences Quarterly report: H1 2026 - Filings
- 24 days ago - Vita Life Sciences Slides: H1 2026 - Filings
- 3 months ago - Vita Life Sciences Transcript: AGM 2026 - Transcripts
- 3 months ago - Vita Life Sciences Slides: FY 2026 - Filings
- 5 months ago - Vita Life Sciences Annual report: H2 2025 - Filings
- 5 months ago - Vita Life Sciences Annual report: H2 2025 - Filings